3 BOARD OF DIRECTORS
INDEPENDENCE AND RULES REGARDING OUTSIDE MANDATES
All the members of the Board of Directors are non-executive members. None of the Board members was formerly a member of the Management Board of Tecan Group Ltd. or any Group company during the period under review or the three preceding periods. According to the Articles of Incorporation the permitted number of other mandates of the members of the Board of Directors in the highest executive management or bodies of legal entities outside of the Company’s group is limited to four mandates in listed and four mandates in non-listed companies, foundations and other legal entities with economic purpose. Mandates in different legal entities of the same group (including in joint ventures directly or indirectly owned by such a group or the Company that are not consolidated) are counted as one mandate per group, but may not exceed the number of 20 additional mandates if counted separately. Mandates held by members of the Board of Directors by order of the Company shall not be subject to the limitations set out above. Conflicts of interest are prohibited by Article 7 of the Articles of Incorporation. Adherence to the Articles of Incorporation is monitored by the Board Secretary, Tecan’s General Counsel. No conflicts of interest have been identified in 2024 or previous years. Should a conflict of interest be detected, it would be addressed and if deemed material, reported to shareholders. Tecan completes external sustainability reporting and is highly rated by agencies including MSCI and ISS for its strong governance practices.
ELECTION, TERM OF OFFICE, ORGANIZATION, MEETINGS AND ATTENDANCE
Pursuant to the Company’s Articles of Incorporation, the Board of Directors is composed of a minimum of one and a maximum of eight members, who are elected for a term of one year. Re-election after the end of the term is permitted. The Chair of the Board of Directors is elected by the General Meeting. The Board of Directors is responsible for the ultimate supervision and management of the Company, including the development of general strategies and guidelines, and for all other duties that are non-transferable under applicable law. To the extent permitted by law and provided that there is no conflict with the Company’s Articles of Incorporation and the Organizational Regulations adopted by the Board of Directors, management of the Company’s affairs is delegated to the Management Board pursuant to the Organizational Regulations. The Board’s performance is reviewed by the Nomination Committee as described in that section of this report; adherence to Tecan’s Articles of Incorporation is monitored by the Board Secretary, Tecan’s General Counsel.
Tecan’s shareholders vote to approve the appointment of Board members or the continuation of their term in office at Tecan’s Annual General Meeting. Otherwise, performance is not formally evaluated. Any report made via Tecan’s independent, third-party operated whistleblower hotline regarding the Board would be investigated by Tecan’s Compliance function, as described previously. The Board of Directors meets as often as business matters require but at least five times a year upon invitation of the Chair or, in their absence, upon invitation of another Board member. Any member of the Board of Directors may call a meeting by specifying the reasons for the meeting. The meetings usually last between five and seven hours. As a general rule, the CEO and CFO attend the Board meetings and other members of the Management Board or senior management invited by the Chair attend for certain portions. At each meeting, the Chair reserves some time for discussion between the members of the Board and the CEO and some time for discussion amongst the Board members only. Meetings may also be held by videoconference or by telephone. The Board of Directors passes its resolutions by an absolute majority of votes of Board members present. In the event of a tie, the Chair of the Board has the deciding vote. Resolutions may be passed in writing unless a member requests oral deliberation. Five Board of Directors’ meetings were held in the year under review. Three meetings of the Audit Committee lasting about two to three hours each were also held. In addition, there were three meetings of the Compensation Committee and several telephone conferences of the Nomination and Governance Committee. In the year under review, all members of the Board of Directors took part in the Board of Directors’ meetings and the committee members attended all of their respective committee meetings.
DR. LUKAS BRAUNSCHWEILER
Chair of the Board and of the Nomination and Governance Committee
Since 2018, elected until 2025
1956
Swiss citizen
PhD in Physical Chemistry,
Swiss Federal Institute of Technology, Zurich (ETH Zurich),
Switzerland
Professional background:
1985 to 1995 various management positions at Wild Leitz Heerbrugg AG (today Leica Geosystems), Switzerland; Huber + Suhner AG, Switzerland; Saurer Group Holding AG, Switzerland; and Landis+Gyr AG (today Siemens AG), Switzerland; 1995 to 2002 Member of the Group Executive Board and Group Vice President, Mettler-Toledo International, Inc. USA/Switzerland; 2002 to 2009 President and CEO, Member of the Board of Directors, Dionex Corporation, USA; 2009 to 2011 CEO, RUAG Holding AG, Switzerland; 2011 to March 2018 CEO, Sonova Holding AG, Switzerland
Other activities:
Sonova Holding AG1, Member of the Board of Directors
DR. CHRISTA KREUZBURG
Chair of the Compensation Committee
Since 2013, elected until 2025
1959
German citizen
Diploma and PhD in Physical Chemistry, Duisburg University, Chemical Faculty
Professional background:
1990 to 1994 Laboratory Head, Central Research at Bayer AG, Germany; 1994 to 1996 Departmental Head, Central Research at Bayer AG, Germany; 1997 to 1999 Strategy Consultant, Corporate Strategic Planning at Bayer AG, Germany; 2000 to 2002 Head of Corporate Strategic Planning, in addition from 2001, leading the restructuring project of division Pharmaceuticals after the withdrawal of Lipobay® at Bayer AG, Germany; 2002 to 2005 Head of Pharma Japan (from 2004)/Europe/MERA and member of the Pharma Management Committee at Bayer HealthCare, Germany; 2006 to 2007 Head of Pharma Primary Care/International Operations and member of the Pharma Management Committee at Bayer HealthCare, Germany; 2007 to 2008 Head of Bayer Schering Pharma Europe/Canada and member of the Executive Committee. Integration of Bayer and Schering in the region at Bayer HealthCare, Germany; 2009 to today consulting projects for small and mid-size healthcare companies
Other activities:
Catalent Inc.1, Member of the
Board (until 25.01.2024)
MATTHIAS GILLNER
Chair of the Audit Committee
Since 2023, elected until 2025
1967
Swiss and German citizen
MBA Degree, INSEAD, Fontainebleau, France & Master Degree in Chemical Engineering, Friedrich-Alexander-University Erlangen-Nuernberg, Erlangen, Germany
Professional background:
1993 to 2000 Manager and various other positions at Boston Consulting Group Inc., Munich, Germany; 2000 various management positions at Hilti Group, Schaan, Liechtenstein; 2011 to 2014 Member of the Executive Board – Electric Tools & Accessories, Corporate Research & Technology, Hilti Group, Schaan, Liechtenstein; 2014 to 2017 Member of the Executive Board – Emerging Markets, Energy & Industry, Hilti Group, Schaan, Liechtenstein; 2017 to 2022 Member of the Executive Board – Finance, Tax, Human Resources, IT, Corporate Development and Energy & Industry, Hilti Group, Schaan, Liechtenstein
Other activities:
Hilti Group2, Member of the Board of Directors; Martin Hilti Family Trust2, Trustee; Hilti Foundation2, Chairperson; Ursula Zindel-Hilti Foundation2, Member of the Foundation Board
MYRA ESKES
Since 2022, elected until 2025
1971
Dutch citizen
Master Degree in Macro Economics, University of Groningen, Groningen, The Netherlands
Professional background:
1995 to 2005 various management positions at General Electric Company, The Netherlands & USA including General Manager Diagnostic Imaging Equipment Manufacturing; 2005 to 2008 Vice President Business Operations, Universal Pictures International Entertainment, UK; 2009 to 2019 various management positions at General Electric Company, Singapore & Turkey including
President and CEO Southeast Asia, Korea, Australia and New Zealand; 2019 to 2023 President Asia Pacific, Smith & Nephew Plc, Singapore
Other activities:
None
DR. OLIVER FETZER
Since 2011, elected until 2025
1964
US citizen MBA, Carnegie Mellon University, Pittsburgh, USA, PhD Pharmaceutical Sciences, Medical University of South Carolina, USA
Professional background:
1993 to 2002 The Boston Consulting Group, USA, between 2000 and 2002 Managing Director and Partner; 2002 to 2007 Cubist Pharmaceuticals USA, various management positions, including Senior Vice President, Corporate Development and Research and Development; 2007 to 2008 Sabbatical; 2009 to 2014 President and Chief Executive Officer, member of the Board of Directors of Cerulean Pharma Inc., USA; 2014 to 2024 President and Chief Executive Officer, Member of the Board of Directors, Viridos Inc., USA
Financial Expertise:
More than ten years of experience as CEO, including taking company public. MS in Industrial Administration (MBA) from Carnegie Mellon. 9 years at the Boston Consulting Group including Partner and Managing Director.
Other activities:
None
DR. KAREN HUEBSCHER
Since 2012, elected until 2025
1963
Swiss and British citizen
MBA, IMD Lausanne; PhD Natural Sciences, ETH Zurich and Master’s degree, Animal
Sciences, ETH Zurich
Professional background:
1995 to 2000 various positions with increasing responsibility in Research and Finance at
CIBA Geigy and Novartis; 2006 to 2009 Member of the Novartis Vaccines & Diagnostics Division's Executive Committee and Innovation Board, with headquarters in the US, in charge of Business Development/Mergers and Acquisitions; 2009 to 2011 Member of the European Commercial Operations Leadership Team and Site Head Novartis Vaccines & Diagnostics, Basel. Head Public Health and Market Access Europe (Marketing & Sales). Board Member European Vaccines Manufacturers’ association in Brussels; since 2012 Founder and Managing Director of Fibula Medical AG; 2013 Member of the Board Solvias Group, 2014 to 2021 CEO Solvias Group2, Headquarters in Kaiseraugst, Switzerland
Financial Expertise:
CEO of Solvias Group2; Novartis Group Head Investor Relations from 2000 to 2006, reporting directly to CFO and Head of Treasury, Member of the Disclosure Committee Novartis, Global Head Mergers and Acquisitions, Division Vaccines & Diagnostics, Novartis
Other activities:
Ivoclar Vivadent AG2, Member of the Board; Sandoz Group AG1, Vice-Chairwoman; BBI Group2, Member of the Board; Nonprofit organizations: SMG (Swiss Management Association)2, Member of the Board until April 2025; IMD2, Member of the Foundation Board
MONICA MONOTAS
Since 2024, elected until 2025
1973
US and Colombian citizen MBA Degree with concentration in Finance and Accounting, William E. Simon Graduate School of Business Administration, University of Rochester, Rochester, NY, USA; Bachelor of Science in Industrial Engineering, Universidad del Norte, Barranquilla, Colombia
Professional background:
1995 to 1996 Consultant at Marun & Frias Management Consultants, Barranquilla, Colombia; 1997 to 1998 Financial Analyst, Americas Customer Operations / Integrated Supply Chain at Xerox Corporation, Rochester, NY, USA; 1999 to 2023 various management positions at Thermo Fisher Scientific, Inc in France, Spain, Switzerland and USA
Financial Expertise:
More than 10 years of experience in finance roles at Thermo Fisher and Xerox Corporation, 14 years of experience as general manager of businesses at Thermo Fisher Scientific, including 7 years as division or group president, MBA degree with concentration in Finance and Accounting from the University of Rochester
Other activities:
None
DR. DANIEL R. MARSHAK
Since 2018, elected until 2025
1957
US citizen
PhD in Biochemistry and Cell Biology, The Rockefeller University, New York, USA; Bachelor in
Biochemical Sciences, Harvard University, Cambridge, USA
Professional background:
1984 to 1986 Staff Fellow, National Institutes of Health, USA; 1986 to 1995 Sr. Staff Investigator, Cold Spring Harbor Laboratory, USA; 1994 to 2000 Sr. Vice President and Chief Scientific Officer, Osiris Therapeutics, Inc.; 2000 to 2006 Vice President and Chief Technology Officer, Biotechnology and Vice President Research and Development, Biosciences, Cambrex Corporation, USA; 2006 to 2014 his last role Senior Vice President and Chief Scientific Officer, additional positions: President, Emerging Diagnostics, Waltham, USA and Shanghai, China; President, Greater China, Shanghai, China; PerkinElmer, Inc., USA; 2014 to present Consultancy for various companies in the Life Sciences, Bio-Pharmaceutical, and Diagnostics industry. Consultant to RADx program of US Government DHHS/NIH/NIBIB for COVID-19 diagnostics
Other activities:
RareCyte, Inc.2, Member of the Board of Directors
- public company
- private company
COMMITTEES
The Board of Directors has appointed committees composed of members of the Board to prepare and implement its resolutions and to exercise its supervisory function. The committees are assigned with specific duties and responsibilities. All other duties and responsibilities remain with the full Board of Directors, for instance the review of the Company’s ESG approach, activities and risks and Cyber Security risks. The committees meet upon invitation of the respective Chair and as often as business requires, but at least twice a year. Committee resolutions and proposals for consideration by the entire Board of Directors are passed by a majority of votes cast, provided that there is a quorum of at least two committee members present. Resolutions may also be passed by written resolution. For specific topics (for example in connection with M&A discussions) the Board of Directors forms ad-hoc committees. Several conference calls of ad-hoc committees were held in the year under review. The Board of Directors has established three committees that are composed as follows:
| Audit Committee | Compensation Committee | Nomination and Governance Committee |
Dr. Lukas Braunschweiler | Member |
| Chair |
Dr. Christa Kreuzburg | Chair | Member | |
Matthias Gillner | Chair |
| Member |
Myra Eskes | Member | ||
Dr. Oliver Fetzer |
| Member |
|
Dr. Karen Huebscher | Member |
| Member |
Monica Manotas | Member | ||
Daniel R. Marshak |
| Member |
|
AUDIT COMMITTEE
The Audit Committee is composed of at least two members. The committee’s principal duties and responsibilities are to form an opinion regarding internal and external audits and to monitor cooperation between the external statutory auditors and the Company; to assess the quality of internal audits and compliance; to review the annual financial statements (both consolidated and single-entity) and interim financial statements destined for publication and report on them to the full Board of Directors; to make recommendations to the full Board of Directors, especially with regard to the approval of annual and interim financial statements; and to monitor the independence, performance and fees of the statutory auditors and propose that they be appointed or reappointed by vote of the Annual General Meeting. This committee is also charged with monitoring the risk management of the Company.
Furthermore, the Audit Committee oversees the Company's reporting obligations and compliance regarding sustainability, in particular regarding environmental, social and governance (ESG) aspects, discuss feedback from investors, proxy advisors and analysts concerning the Company's performance in ESG matters, and generally assists the Board of Directors and support the Management in responding to ESG related questions. Representatives of the external statutory auditors and the internal auditor may attend meetings of this committee at the invitation of the Chair. The experience in financial matters of members of the Audit Committee are set out on pages 104 and 105.
COMPENSATION COMMITTEE
The majority of members of the Compensation Committee must be non-executive and independent members of the Board of Directors. The role and responsibilities of the Compensation Committee are described in the Compensation Report on page 114 and 131.
NOMINATION AND GOVERNANCE COMMITTEE
The majority of members of the Nomination and Governance Committee must be independent and non-executive members of the Board of Directors. The committee consists of three members. It is chaired by the Chair of the Board. The most important duties of this committee include performance review and succession planning at the level of the Board of Directors and the Management Board; defining the selection criteria for members of the Board of Directors and the Management Board; and regularly reviewing the performance of the Board of Directors, its committees and its individual members based on a set of overall competences of the Board required for the Company. This committee is also charged with monitoring risk management and corporate governance.
INFORMATION AND CONTROL INSTRUMENTS
The members of the Management Board are actively involved in the various committees of the Board of Directors. The CEO, CFO, the General Counsel and the internal auditors and sometimes the external statutory auditors attend the meetings of the Audit Committee, for example. In addition, members of the Management Board meet with individual Board members on an ad-hoc basis to discuss and delve more deeply into specific topics. Through these meetings, critical concerns could be raised. No critical concerns impacting stakeholders were raised in 2024.
The Board of Directors receives monthly reports from the Group’s management information system so that it can monitor financial and operational performance. All relevant guidelines are presented to the Board of Directors or the appropriate committees for approval to ensure shared responsibility for all major decisions.
Internal Audit: Since the internal auditors report to the Audit Committee, their independence is assured. All companies are audited every three years on the basis of a risk analysis. The annual audit plan consists of audits of all major companies and is approved by the Audit Committee. A summary of significant findings and recommendations is submitted directly to the Audit Committee with copies to the CEO, the CFO and the General Counsel. The reports are also made available to the external statutory auditors. During the year under review, Internal Audit focused its efforts on strengthening the internal control system for financial reporting and compliance. Other areas audited include compliance with laws and standards; the compliance, efficiency and effectiveness of business processes; improved cyber security measures; and the implementation of recommendations made by the internal auditors. Additional information on risk management is given in Note 12 to the financial statements of Tecan Group Ltd..